Heidi Ko/LinkedIn
Mar 4, 2025, 11:22
Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on LinkedIn:
“Excited to share that our latest mini-review on HER2 as a tumor-agnostic biomarker is now published in Frontiers in Oncology!
We delved into the evolving role of HER2 overexpression in various solid tumors and discussed how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies.
We also addressed the challenges in HER2 testing across pan solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.
Check out the full article here.”
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.
Authors: Heidi C Ko, et al.
More posts featuring Heidi Ko.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 01:36
Apr 22, 2025, 19:24
Apr 22, 2025, 18:28
Apr 22, 2025, 17:31
Apr 22, 2025, 16:58